4506

Sumitomo Pharma Co.,Ltd.

住友ファーマ

Industry
Pharmaceutical
Market
Prime
Accounting standards
IFRS
Consolidation basis
Consolidated

Key metrics

Revenue(million JPY)

Mar 2022
560,035
Mar 2023
555,544
Mar 2024
314,558
Mar 2025
398,832
Mar 2026
453,294

Operating profit(million JPY)

Mar 2022
60,234
Mar 2023
-76,979
Mar 2024
-354,859
Mar 2025
28,804
Mar 2026
107,338

Operating profit margin(%)

Mar 2022
10.76
Mar 2023
-13.86
Mar 2024
-112.81
Mar 2025
7.22
Mar 2026
23.68

Profit before tax(million JPY)

Mar 2022
82,961
Mar 2023
-47,920
Mar 2024
-323,114
Mar 2025
17,611
Mar 2026
100,344

Profit(million JPY)

Mar 2022
56,413
Mar 2023
-74,512
Mar 2024
-314,969
Mar 2025
23,634
Mar 2026
106,865

Total assets(million JPY)

Mar 2022
1,308,007
Mar 2023
1,134,742
Mar 2024
907,506
Mar 2025
742,604
Mar 2026
804,571

Cash and cash equivalents(million JPY)

Mar 2022
202,984
Mar 2023
143,478
Mar 2024
29,047
Mar 2025
23,116
Mar 2026
44,310

Cash flows from operating activities(million JPY)

Mar 2022
31,239
Mar 2023
11,937
Mar 2024
-241,893
Mar 2025
16,500
Mar 2026
71,715

Cash flows from investing activities(million JPY)

Mar 2022
-18,278
Mar 2023
52,419
Mar 2024
33,036
Mar 2025
99,754
Mar 2026
22,549

Cash flows from financing activities(million JPY)

Mar 2022
-21,426
Mar 2023
-146,817
Mar 2024
77,851
Mar 2025
-108,836
Mar 2026
-91,266

Return on equity(%)

Mar 2022
9.5
Mar 2023
-14.7
Mar 2024
-111.9
Mar 2025
14.5
Mar 2026
46.3

Equity ratio(%)

Mar 2022
46.5
Mar 2023
35.8
Mar 2024
17.2
Mar 2025
22.8
Mar 2026
36.4

Earnings per share(JPY per share)

Mar 2022
141.99
Mar 2023
-187.55
Mar 2024
-792.79
Mar 2025
59.49
Mar 2026
268.99

Net assets per share(JPY per share)

Mar 2022
1,530.08
Mar 2023
1,023.8
Mar 2024
392.82
Mar 2025
426.59
Mar 2026
736.16

Dividend per share(JPY per share)

Mar 2022
28
Mar 2023
21
Mar 2024
-
Mar 2025
-
Mar 2026
-

Payout ratio(%)

Mar 2022
19.72
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-

Disclaimer

The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.

The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.